welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer.
The drug, CPP-1X, will be studied in patients with precancerous gastric lesions who are at high risk for gastric cancer, the company said Monday.
The trial is funded by the National Cancer Institute and run in collaboration with gastroenterologists Dr. Keith T. Wilson and Dr. Douglas R. Morgan of the Vanderbilt University School of Medicine and the Vanderbilt-Ingram Cancer Center.
expertly curated content related to this topic
Poster Presentation Objective: This s...
Our Experience of Treatment of Cribriform Morular Variant of Papillary Thyroid Carcinoma; Difference in Clinicopatho...Cribriform-morular variant (CMV) is a co...
IMPORTANCE OF THE FIELD : An important r...
PURPOSE : A study was performed to evalu...
Colorectal cancer (CRC) is a major cause...
This book explains colon polyps and thei...